An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma

Trial Profile

An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Omaveloxolone (Primary) ; Ipilimumab; Nivolumab
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms REVEAL
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 11 Dec 2017 Interim result from phase 1b portion of the this trial presented in a Reata Pharmaceuticals Media Release.
    • 11 Dec 2017 According to a Reata Pharmaceuticals media release, interim data from phase 1b portion of the this trial were presented at the European Society for Medical Oncology (ESMO) Immuno Oncology Congress 2017.
    • 31 Mar 2017 Planned number of patients changed from 84 to 102.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top